CJC-1295 (no DAC) is a synthetic 30-residue analog of GHRH(1-29) with four amino acid substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) that enhance plasma stability and GHRH-receptor potency. Without the drug-affinity complex (DAC) modification, the peptide retains the natural pulsatile pharmacokinetics of GHRH agonism.
Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped ~4 days from our lab.
Research applications
GHRH-receptor binding assays, in-vitro pituitary GH-secretion screens, and comparative pharmacokinetics versus DAC-modified analogs and natural GHRH(1-29).
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0-2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Storage after reconstitution
Reconstituted solution is stable for 28 days at 2-8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805.
CJC-1295 is a GHRH analog, classified within the growth-axis signaling pathway. Structurally it is a 30-residue D-Ala-modified GHRH. CJC-1295 (no DAC) is a synthetic 30-residue analog of growth-hormone-releasing hormone (GHRH 1-29) with substitutions at positions 2, 8, 15, and 27 conferring DPP-IV resistance and extended half-life. Teichman et al. (2006) characterized its pharmacokinetics.
In an in-vitro setting, CJC-1295 interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable until reconstituted.
Common research applications
In-vitro receptor-binding and dose-response screens against the growth-axis signaling target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging CJC-1295's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA (available on request).
Storage & handling
CJC-1295 arrives lyophilized in Canada Post (~4 days). On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
References
Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805.
Sigalos JT, Pastuszak AW. Sex Med Rev. 2018;6(1):86-90.
Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91(12):4792-7.
For laboratory research only. CJC-1295 is sold strictly as an in-vitro reference standard. Sold as an in-vitro reference standard, not as a Health Canada or FDA-approved therapeutic.
